In development: Guidance, quality standards and advice
Showing 401 to 406 of 406
Title | Type | Expected publication date |
---|---|---|
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392] | Technology appraisal guidance | |
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079] | Technology appraisal guidance | TBC |
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008] | Technology appraisal guidance | TBC |
Zio XT for detecting cardiac arrhythmias | Medical technologies guidance | TBC |
Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123] | Technology appraisal guidance | TBC |
Zuranolone for treating severe postnatal depression ID6431 | Technology appraisal guidance | TBC |